Revolution Medicines
RVMD
Performance
About Revolution Medicines
Revolution Medicines is a biopharmaceutical company focused on discovering, developing, and delivering targeted medicines for cancer, with a particular emphasis on Ras-driven or Ras-addicted cancers. The company pursues precision oncology through its pipeline and science programs, aiming to outsmart cancer by targeting oncogenic pathways. Headquartered in Redwood City, California, Revolution Medicines emphasizes translational science and novel targeted therapies to treat patients worldwide.
Recent News
Merck Backs Off Revolution After Failing To Agree on Price: WSJ
Revolution Medicines' Daraxonrasib Shows Survival Gain, Stock Up 39%
Daraxonrasib (RMC-6236): The 2025 Molecule of the Year
Former Sen. Ben Sasse Shines the Spotlight on a Possible Breakthrough for Pancreatic Cancer
This Pill May Help Pancreatic Cancer Patients Live Longer
Revolution Medicines Initiates P-III (RASolute 303) Trial of Daraxonrasib in Pancreatic Ductal Adenocarcinoma (PDAC)
Merck to Acquire Terns Pharmaceuticals for $6.7 B, Accelerating M&A Ahead of Keytruda Patent Expiry
Report Says MSD Is in Talks to Buy Revolution Meds
Former Senator Ben Sasse Joins Daraxonrasib Trial, Tumors Shrink 76% in Pancreatic Cancer
Revolution Rises 40% as Pancreatic Cancer Drug Doubles Survival
Abivax Climbs on Lilly Takeover Speculation
Revolution Medicines' Pancreatic Cancer Drug Doubles Survival Time in Phase 3
Behind the Headlines Episode 32: AI’s Power, NVIDIA & Lilly, Revolution Medicine
Speculation Builds About a Deal for Revolution Medicines
STAT+: Revolution Medicines Touts ‘Unprecedented’ Data for Pancreatic Cancer Pill
The Wild Card in the G12D Space
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline
Revolution Medicines Leads Latest Wave of Stock Offerings, Totaling $1.5B
Top 10 Most Popular Drug Hunter Case Studies of 2025
JPM 2026: What’s the Outlook Like This Year?
STAT+: Pharmalittle: We’re Reading About a Pancreatic Cancer Pill, FDA Rejecting a Replimune Drug Again, and More
